Results 151 to 160 of about 297,165 (214)
Progress of Myeloid-Associated Antigens Such as CD7 and CD19 in AML
openaire +1 more source
Computer-guided dosing of multi-specific T-cell engagers. [PDF]
Kendell I +9 more
europepmc +1 more source
A multimodal viro-immunotherapy strategy for glioblastoma. [PDF]
Li J, Shi Y.
europepmc +1 more source
Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy. [PDF]
Riet T +7 more
europepmc +1 more source
Multi-dimensional orchestration of binders for improved CAR-T immunotherapy. [PDF]
Zhu C, Jiang Z, Jing R, Guo W, Lu Y.
europepmc +1 more source
CAR T cells against the B cell receptor to precisely eliminate pathogenic B cells. [PDF]
Bochi-Layec AC +3 more
europepmc +1 more source
CAR-T-cell therapy for autoimmune neurologic diseases. [PDF]
Zhao Y +6 more
europepmc +1 more source
Progress and promise of CAR-T cell treatment in autoimmune diseases. [PDF]
Bachl J, Hagen M, Schett G.
europepmc +1 more source
CAR-T cell therapy is not without some clinical adverse effects, namely cytokine storms, due to a massive release of cytokines when CAR-T cells multiply in the body.
Shabirul Haque
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
CD19 CAR antigen engagement mechanisms and affinity tuning
Science Immunology, 2023Chimeric antigen receptor (CAR) T cell therapy relies on T cells that are guided by synthetic receptors to target and lyse cancer cells. CARs bind to cell surface antigens through an scFv (binder), the affinity of which is central to determining CAR T cell function and therapeutic success.
Changhao He +11 more
openaire +2 more sources

